Skye Bioscience (SKYE) grants CFO 125,000 options at $0.82

Rhea-AI Filing Summary

Skye Bioscience reported that its Chief Financial Officer, Kaitlyn Arsenault, received a grant of stock options on February 6, 2026. The award covers 125,000 options to buy common stock at an exercise price of $0.82 per share. The options vest in equal monthly installments over a four-year period beginning January 19, 2026, aligning her long-term compensation with the company’s share performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ARSENAULT KAITLYN

(Last) (First) (Middle)

11250 EL CAMINO REAL, SUITE 100

C/O SKYE BIOSCIENCE, INC.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.82	02/06/2026		A		125,000		(1)	02/06/2036	Common Stock	125,000	$0	125,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026.

Remarks:

	/s/ Kaitlyn Arsenault	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Skye Bioscience (SKYE) report for its CFO?

Skye Bioscience reported a stock option grant to Chief Financial Officer Kaitlyn Arsenault. She received 125,000 stock options on February 6, 2026, giving her the right to purchase Skye Bioscience common stock at a fixed exercise price of $0.82 per share.

What are the key terms of Kaitlyn Arsenault’s 125,000 Skye Bioscience stock options?

The grant consists of 125,000 stock options with an exercise price of $0.82 per share. The options were granted on February 6, 2026 and relate to Skye Bioscience common stock, providing potential future ownership if exercised.

How do the Skye Bioscience stock options for the CFO vest over time?

The stock option award vests in equal monthly installments over four years. Vesting begins on January 19, 2026, meaning a portion of the 125,000 options becomes exercisable each month until fully vested at the end of the four-year period.

What is the expiration date for the CFO’s Skye Bioscience stock options?

The stock options granted to the CFO expire on February 6, 2036. After this expiration date, any unexercised portion of the 125,000 options will no longer be exercisable, limiting the time window to benefit from the $0.82 exercise price.

How many Skye Bioscience derivative securities does the CFO hold after this Form 4?

Following the reported transaction, the CFO beneficially owns 125,000 derivative securities in the form of stock options. These options relate to Skye Bioscience common stock and are held with direct ownership, as indicated by the filing’s ownership classification.

What role does Kaitlyn Arsenault hold at Skye Bioscience (SKYE) in this Form 4?

The reporting person in the Form 4, Kaitlyn Arsenault, serves as Chief Financial Officer of Skye Bioscience. The filing identifies her specifically as an officer, not a director or 10% owner, in connection with this stock option grant.